iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024

Core Viewpoint - iTeos Therapeutics, Inc. (NASDAQ: ITOS) presents a generally favorable investment thesis, but careful consideration of associated risks is necessary [1] Company Analysis - The company has been covered multiple times, indicating ongoing interest and analysis in its performance and potential [1] - The author possesses a PhD in biochemistry and extensive experience in analyzing clinical trials and biotech companies, which adds credibility to the insights provided [1] Industry Insights - There is a strong emphasis on the importance of understanding the science behind biotech investments, highlighting the complexity and potential pitfalls in this sector [1]